Numinus Announces Grant of Stock Options

VANCOUVER, BC, June 24: Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it has granted 1,825,000 incentive stock options (the "Options") to directors, officers and employees of the Company, which are subject to regulatory approval. Of the 1,825,000 Options granted during the month of May, 810,000 were issued to directors and an officer of Numinus, which have an exercise price of $0.90 per common share and are exercisable until May 19, 2023. The 1,015,000 Options issued to employees have exercise prices ranging between $0.87 and $1.00 with expiry dates ranging from May 1, 2023 to May 17, 2023. The Company's Stock Option Plan allows for the issuance of up to 10% of issued and outstanding share capital in the form of incentive stock options. As the result of the above grants, the Company has 8,931,500 options issued, representing approximately 4.42% of the issued and outstanding share capital. About Numinus Numinus Wellness (TSX-V: NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society. Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.